AlphAIAlphAI — Financial news for AI agents
investing.comSEP 222 min read$CLDX

Why is Celldex Therapeutics stock sliding today?

Celldex Therapeutics (CLDX) stock fell 10.4% after Phase 3 trial results for barzolvolimab met primary and secondary endpoints but showed smaller efficacy gains than Phase 2. Analysts maintained positive ratings and price targets. The broader market had minimal impact, highlighting the company-specific move.

Original reporting
investing.com
Published Sep 22, 2026, 5:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 5:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLDX
Bearish
high confidence
Mentioned
$CLDX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLDXBearishHigh
01

Why it matters

The data triggered a sell‑the‑news move, dropping the stock 10.4% intraday despite continued regulatory optimism.

02

Market read

The primary relevance is to CLDX shareholders; broader market impact is minimal.

03

What to watch

Regulatory pathway remains intact and a 2027 BLA filing is still on track.

Relevance 8/10Novelty 9/10Timing: mid‑day trading today

Background

Celldex Therapeutics announced Phase 3 results for its CSU drug barzolvolimab, which met endpoints but under‑performed Phase 2 expectations.

Company-level read

Ticker impact

$CLDXBearishHigh confidence
Context

Phase 3 trial data for barzolvolimab caused a 10.4% intraday drop in CLDX stock.

Expected impact

Further downside risk if data fails to improve or regulatory concerns arise.

Evidence & confidence

Investors had built expectations; the 10‑point placebo‑adjusted improvement fell short, prompting sell‑the‑news pressure.

Market effects

Sector

Highlights competitive pressure in chronic spontaneous urticaria market; peers may see valuation pressure.

Regional

US biotech sector may see modest pullback as investors reassess Phase 3 expectations.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Long‑term investors may view the data as still clinically meaningful and buy on dip.

Key entities

  • company
    Celldex Therapeutics

    Biotech firm developing barzolvolimab for chronic spontaneous urticaria.

  • company
    Novartis

    Competitor marketing omalizumab in the same therapeutic area.

  • company
    Roche

    Competitor with similar CSU treatments.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 23
$CLDXMedAI 8/10

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.

investing.com2 min
SEP 23
$CLDXHighAI 9/10

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting all primary and secondary endpoints. The drug showed significant efficacy, with a majority of patients achieving complete symptom relief. However, the company faces high R&D costs and a 2027 expected BLA filing. CLDX has $717.6M in cash and a pipeline of other studies, but a recent Phase 2 failure in prurigo nodularis highlights risks.

insidermonkey.com3 min
SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min
SEP 22
$CLDXMedAI 8/10

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both studies met primary and secondary endpoints, showing significant symptom improvement. The treatment also showed sustained efficacy and a favorable safety profile. CLDX plans to submit a Biologics License Application to the FDA in 2027. Shares initially rose but later fell 12.51% to $36.65.

benzinga.com2 min